Gsk (GLAXF) Net Income - Minority (2009)

Gsk (GLAXF) recorded quarterly Net Income - Minority of -$1.2 billion in Q4 2009, down 107.26% quarter-over-quarter from -$580.8 million in Q3 2009.

Gsk (GLAXF) Net Income - Minority (2009) Analysis & Trends

Gsk's Net Income - Minority history runs 1 years deep, the most recent figure standing at -$1.2 billion for Q4 2009.

In Q4 2009, Net Income - Minority changed N/A year-over-year to -$1.2 billion; the TTM figure through Dec 2009 stood at -$1.2 billion (changed N/A YoY), while the FY2009 annual figure was -$1.2 billion, changed N/A from the prior year.
Net Income - Minority was -$1.2 billion for Q4 2009 at Gsk, down from -$580.8 million in the prior quarter.
In the past five years, Net Income - Minority ranged from a high of -$486.2 million in Q2 2009 to a low of -$1.2 billion in Q4 2009.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Net Income - Minority (Qtr)
1	Gsk	93,699,046.73 Bn	93,699,041.77 Bn	7.76 Bn	-
2	Eli Lilly	1,012.06 Bn	1,006.77 Bn	16.22 Bn	-
3	Johnson & Johnson	560.67 Bn	538.62 Bn	15.96 Bn	-
4	AbbVie	402.20 Bn	392.85 Bn	10.78 Bn	-
5	Merck	298.59 Bn	292.94 Bn	12.09 Bn	-
6	Amgen	188.77 Bn	176.74 Bn	5.87 Bn	-
7	Gilead Sciences	160.22 Bn	152.49 Bn	5.52 Bn	-
8	Pfizer	148.19 Bn	135.42 Bn	-1.21 Bn	-
9	Bristol Myers Squibb	116.72 Bn	106.26 Bn	8.07 Bn	-
10	Gsk	-	-	7.76 Bn	-

Download Data